arthritis

IRP’s John O’Shea Elected to National Academy of Sciences

NIH Scientist Spurred Revolution in Autoimmune Disease Therapy

Dr. John O'Shea

IRP senior investigator John O’Shea, M.D., is a man of many talents. During his career at NIH, he has applied his creativity and drive not just to playing a variety of instruments in a rock band made up of NIH scientists, the Affordable Rock ‘n’ Roll Act (ARRA), but also to his groundbreaking research on the immune system.

This May, Dr. O’Shea, who is the Scientific Director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), was elected to the National Academy of Sciences (NAS) for his influential research on the biochemical chain of events that kicks our immune system into gear, which has led to a better understanding of how genetic mutations interfere with the immune response, as well as the development of an entire new class of drugs that target the immune system.

Genetic Sequencing Solves Drug Reaction Mystery

Immune System Genes Linked to Severe Side Effects in Patients with Rare Disease

computer monitor showing the results of DNA sequencing

When you run the largest-ever study of a rare childhood disease, you become the go-to person when your peers notice something peculiar in patients with the illness. It was not too surprising, then, when a researcher from Stanford University in Palo Alto, California, asked IRP investigator Michael Ombrello, M.D., to help her team follow a new lead in the mystery of why some patients with a rare inflammatory condition called Still’s disease were coming down with a life-threatening lung ailment. The results of their collaboration could lead to a new precision medicine approach that individualizes therapy for Still’s disease based on patients’ DNA.